Published in J Steroid Biochem Mol Biol on December 19, 2004
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets (2009) 1.66
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol (2007) 1.43
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res (2010) 1.17
Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci (2007) 1.13
Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis (2008) 1.12
Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med (2006) 1.12
PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer (2012) 1.11
Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate (2009) 1.08
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol (2006) 1.06
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther (2009) 1.02
CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget (2014) 0.95
Androgen regulation of the androgen receptor coregulators. BMC Cancer (2008) 0.92
Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res (2013) 0.92
Acetylation and nuclear receptor action. J Steroid Biochem Mol Biol (2010) 0.89
Tat-binding protein-1 (TBP-1), an ATPase of 19S regulatory particles of the 26S proteasome, enhances androgen receptor function in cooperation with TBP-1-interacting protein/Hop2. Endocrinology (2009) 0.88
HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia (2009) 0.87
Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation. Mol Cells (2011) 0.87
Quantitative detection of the ligand-dependent interaction between the androgen receptor and the co-activator, Tif2, in live cells using two color, two photon fluorescence cross-correlation spectroscopy. Eur Biophys J (2006) 0.86
STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Mol Cancer Ther (2008) 0.86
Insulin-like growth factor-binding protein-5-induced laminin gamma1 transcription requires filamin A. J Biol Chem (2010) 0.85
Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells. PLoS One (2014) 0.83
Pax6 represses androgen receptor-mediated transactivation by inhibiting recruitment of the coactivator SPBP. PLoS One (2011) 0.82
Interleukin-4 activates androgen receptor through CBP/p300. Prostate (2009) 0.81
Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. J Biomed Biotechnol (2010) 0.80
New therapeutics to treat castrate-resistant prostate cancer. ScientificWorldJournal (2013) 0.79
Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget (2015) 0.77
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cell Signal (2016) 0.77
Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity. Am J Cancer Res (2015) 0.75
The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. Sci Rep (2015) 0.75
mRNA expression of steroidogenic enzymes, steroid hormone receptors and their coregulators in gastric cancer. Oncol Lett (2017) 0.75
ING3 promotes prostate cancer growth by activating the androgen receptor. BMC Med (2017) 0.75
Androgen receptor coactivator p120 subtype β is highly expressed in prostate cancer. Prostate Int (2013) 0.75
Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity. Oncotarget (2016) 0.75
Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol (2007) 9.67
Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol (2004) 3.15
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology (2004) 2.68
Adult stem cell therapy of female stress urinary incontinence. Eur Urol (2007) 2.48
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol (2002) 2.37
Retracted Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet (2007) 2.35
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A (2009) 2.33
Total reconstruction of the vesico-urethral junction. BJU Int (2008) 2.28
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
Optimizing the outcome of microsurgical subinguinal varicocelectomy using isosulfan blue: a prospective randomized trial. J Urol (2006) 2.15
Early diagnosis and straight forward surgery of an asymptomatic primary angiosarcoma of the kidney led to long-term survival. Int J Urol (2006) 1.92
Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int (2008) 1.83
Anderson-Hynes dismembered pyeloplasty performed using the da Vinci robotic system. Urology (2002) 1.81
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology (2007) 1.69
Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate (2005) 1.68
Robotic-assisted laparoscopic partial nephrectomy: surgical technique and clinical outcomes at 1 year. BJU Int (2008) 1.68
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Robotic Anderson-Hynes pyeloplasty: 5-year experience of one centre. BJU Int (2007) 1.67
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol (2005) 1.67
Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int (2008) 1.58
Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. BJU Int (2007) 1.55
Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications. J Urol (2004) 1.54
Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction. BJU Int (2008) 1.52
Androgen axis in prostate cancer. J Cell Biochem (2006) 1.48
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol (2004) 1.44
Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int (2007) 1.44
Giant cystine stone in an infant bladder with no evidence of cystinuria--valence of possible pathomechanisms. Urol Int (2005) 1.44
Endoscopic application of dextranomer/hyaluronic acid copolymer in the treatment of vesico-ureteric reflux after renal transplantation. BJU Int (2010) 1.44
Functional and histological changes after myoblast injections in the porcine rhabdosphincter. Eur Urol (2007) 1.43
Model-based optimal design of polymer-coated chemical sensors. Anal Chem (2003) 1.43
Blunt renal trauma in children: 26 years clinical experience in an alpine region. Eur Urol (2002) 1.42
Influence of nitrate levels in drinking water on urological malignancies: a community-based cohort study. BJU Int (2005) 1.41
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol (2003) 1.40
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res (2002) 1.37
Late penile metastasis from primary bladder carcinoma. Urology (2003) 1.32
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
Androgen receptor cross-talk with cell signalling pathways. Growth Factors (2004) 1.31
Amniotic fluid and placental stem cells. Methods Enzymol (2006) 1.30
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer (2008) 1.30
The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl) (2012) 1.23
Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol (2006) 1.21
Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J Steroid Biochem Mol Biol (2006) 1.19
A comparison of laparoscopic pyeloplasty performed with the daVinci robotic system versus standard laparoscopic techniques: initial clinical results. Eur Urol (2002) 1.18
Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol (2007) 1.17
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int (2008) 1.17
Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer (2005) 1.15
Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother (2004) 1.15
Early complications of cystectomy after high dose pelvic radiation. J Urol (2010) 1.14
Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results. Urology (2003) 1.14
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res (2007) 1.12
Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate (2005) 1.12
Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res (2005) 1.11
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res (2005) 1.10
Anatomical radical retropubic prostatectomy: 'curtain dissection' of the neurovascular bundle. BJU Int (2005) 1.10
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res (2009) 1.09
Prostate cancer diagnosis: value of real-time elastography. Abdom Imaging (2008) 1.09
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
Androgen receptors in prostate cancer. J Urol (2003) 1.07
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate (2004) 1.06
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer (2012) 1.06
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol (2006) 1.05
Occurrence of polyorchidism in a young man. Urology (2002) 1.05
The proximal neurovascular plate and the tri-zonal neural architecture around the prostate gland: importance in the athermal robotic technique of nerve-sparing prostatectomy. BJU Int (2006) 1.03
Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol (2008) 1.02
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer (2009) 1.02
Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One (2013) 1.02
Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. Eur Urol (2013) 1.01
Molecular effects of the isoflavonoid genistein in prostate cancer. Clin Prostate Cancer (2005) 1.01
Optimizing the operative treatment of boys with varicocele: sequential comparison of 4 techniques. J Urol (2003) 1.00
Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res (2010) 1.00